About us
The mission of Accupulse is to treat Atrial Fibrillation (AF) with cutting-edge medical innovations in order to ensure a healthier lifestyle to over 33 million people currently suffering with AF. Nowadays, AF is a global epidemic with worldwide 33million people suffering from it. Cardiac catheter ablation is the major interventional therapy using Radio Frequency (RF) or Cryo as the most common sources of energy. However, both RF and Cryo have limitations in acute safety outcomes and the long term clinical results due to their thermal nature. To satisfy these unmet clinical needs, AccuPulse is developing novel pulsed electric field ablation (PFA) generator and catheters, guided by a novel 3D mapping navigation system with better catheter localization, signal acquisition and more intelligent intergation.
Founded in November, 2020, AccuPulse is dedicated to become a globally leading innovator in cardiac electrophysiology industry. The core team members are gathering from industry giants such as Johnson & Johnson, GE, Acutus Medical and Abbott, and has in-depth experience in R&D, registration, and commercialization of cardiac electrophysiological medical devices. Since its establishment, the company has built R&D centers in both China and the United States and the team is led by well-known electrophysiological experts in the United States and backed by top scientists, physicians and famous venture capital firms.
Core members


Founder & CEO

Jay is a seasoned healthcare venture capitalist and a veteran in medical device innovation. Before founding AccuPulse, Jay was a partner in YuanBio Venture, a leading VC focused on early-stage healthcare investment in China. Previously, Jay was with Qiming Venture Partners, one of the most recognized venture capital firm in China with US$ 6.5Bn asset under management. In Yuanbio and Qiming Ventures, Jay invested in over 30 companies with capital deployment >320million USD. His investment cases include: Sanyou Medical (SH:688085), APT Medical (SH:688617), MicroTech (HK:02235), Aohua (SH: 688212), ZyloxTonbridge(HK:02190), Bioheart (HK:02185), Infervision, etc.

Prior to Qiming, Jay was Business Development Director in MicroPort Medical, where he helped MicroPort to accomplish multiple international and domestic acquisition and built up the first joint venture in China with full range of CRM devices between Sorin Medical and MicroPort. Before joining MicroPort in 2012, Jay also worked at GE healthcare and Johnson & Johnson in various business development & marketing positions, launched multiple cardiovascular medical device products in the US and China markets, including Carto 3 3D mapping system in China.

He holds an MBA degree from IMD, Lausanne, Switzerland and a Bachelor of Economics degree from Shanghai University of Finance and Economics.

Marcus Julian


Marcus has Over 35 years experience in start-up companies developing and launching a wide range of disruptive technologies. Before coming to Accupulse, Marcus was VP of Engineering at Tula Health.

Prior to Tula Health, Marcus was involved at the inception of Acutus Medical as a Technical Fellow. He was responsible for the architecture and design of the electronics for Acutus' 3D dipole density system. In the process, he built world class hardware and systems engineering organizations. He is the recipient of many patents related to the Acutus system.

Prior to Acutus, Marcus was the hardware technical founder of Tandem Diabetes. In his role as Director of Engineering and Senior Scientist, Marcus built Tandem's hardware engineering team and employed commercially available low-cost electronics to design the first wearable medical device with a color touch screen and patient isolated USB connection and charging.

At Cameron Health (purchased by Boston Scientific) Marcus was Senior Principal analog engineer responsible for the design of the mixed signal ASIC used in the worlds first lead-less implantable defibrillator.

He holds a BSEE from the Massachusetss Institute of Technology.

Xiangming Zhang

Product Development & Medical Affairs Director

Xiangming Zhang, got his B.S of Engineering Mechanics and Ph.D of Solid Mechnics in Tsinghua University and another Ph.D of Bioengineering in the Univeristy of Oklahoma. He had more than 15 years of research experice in biomedical engineering and medical devices and has published about 20 peer-reviewed journal papers.

Prior to Accupulse, Xiangming worked in the leading electrophysiology technology company, Biosense Webster Inc (a medical device company of Johnson & Johnson) and participated in development, pre-clinical testing and clincial trials of multiple new diagnostic and theraputic products treating atrial fibrililation. He has deep understanding of the radiofrequency and pulse-field abaltion technologies and three dimensional cardiac mapping system.

Prior to Johnson and Johnson, Xiangming worked in Loma Linda VA health Center and the University of Oklahoma. His researches focused on the sound transferring and emission functions in mddle and inner ear. He developped the most comprehensive 3D finite element modeling of human ears in normal and various disordered conditions at that time and measured the dynamic properties of ear tissues in acoustic frequency ranges.

AccuPulse Medical Technology Co.Ltd


Add:9 Suhong W. Rd., Building #6,Suite 201 Suzhou Industrial Park, Jiangsu, China